FRT vs ZBIO · rev $1.28B vs rev $10.0M
FRT (FRT) versus Zenas BioPharma, Inc. Common Stock (ZBIO) — a side-by-side from cached financials, not a winner call.
FRT (FRT) common stock.
Zenas BioPharma, Inc. Common Stock (ZBIO) is a biotechnology company listed on US.
Latest reported FRT revenue for 2025-12-31 was $1.28B. Net income was $411.1M. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. FRT currently screens at market cap $0.
Latest reported ZBIO revenue for 2025-12-31 was $10.0M. Net income was -$377.7M. Revenue was up 100.0% from 2024-12-31 to 2025-12-31. ZBIO currently screens at market cap $798.0M.
FRT currently screens at market cap $0. ZBIO currently screens at market cap $798.0M.
Not investment advice. Open the FRT and ZBIO stock pages for the full models.
Not investment advice.